Paul Reider
Corporate Officer/Principal presso COHERUS BIOSCIENCES, INC.
Patrimonio netto: 147 924 $ in data 31/05/2024
Profilo
Paul Reider is the founder of Raven Management, LLC, which was founded in 2013.
He is currently a Member-Clinical Advisory Board at Tetraphase Pharmaceuticals, Inc. and the Chief Commercial Officer at Coherus BioSciences, Inc. since 2021.
Previously, he was the Vice President-Sales & Strategic Accounts at Puma Biotechnology, Inc. from 2019 to 2021 and the General Manager at Ipsen Biopharmaceuticals Canada, Inc. from 2015 to 2018.
He also worked as a Principal at Amgen, Inc. Mr. Reider holds an undergraduate degree and an MBA from Bowling Green State University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 09/04/2024 | 81 277 ( 0.07% ) | 147 924 $ | 31/05/2024 |
Posizioni attive di Paul Reider
| Società | Posizione | Inizio |
|---|---|---|
| COHERUS BIOSCIENCES, INC. | Corporate Officer/Principal | 01/01/2021 |
| TETRAPHASE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Precedenti posizioni note di Paul Reider
| Società | Posizione | Fine |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Vendite & Marketing | 01/01/2021 |
| Ipsen Biopharmaceuticals Canada, Inc. | Corporate Officer/Principal | 01/01/2018 |
| AMGEN INC. | Corporate Officer/Principal | - |
Formazione di Paul Reider
| Bowling Green State University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
| Ipsen Biopharmaceuticals Canada, Inc. |
- Borsa valori
- Insiders
- Paul Reider
